Land: Malta
Tungumál: enska
Heimild: Medicines Authority
FLUDARABINE PHOSPHATE
Genzyme Europe BV Paasheuvelweg 25, 1105 BP Amsterdam , Netherlands
L01BB05
FLUDARABINE PHOSPHATE 10 mg
FILM-COATED TABLET
FLUDARABINE PHOSPHATE 10 mg
POM
ANTINEOPLASTIC AGENTS
Authorised
2007-12-05
PACKAGE LEAFLET: INFORMATION FOR THE USER FLUDARA ORAL 10 MG FILM-COATED TABLETS Fludarabine phosphate READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Fludara oral is and what it is used for 2. What you need to know before you take Fludara oral 3. How to take Fludara oral 4. Possible side effects 5. How to store Fludara oral 6. Contents of the pack and other information 1. WHAT FLUDARA ORAL IS AND WHAT IT IS USED FOR Fludara oral contains the active substance fludarabine phosphate which stops the growth of new cancer cells. All cells of the body produce new cells like themselves by dividing. Fludara oral is taken up by the cancer cells and stops them dividing. _ _ In cancers of the white blood cells (such as _chronic lymphocytic leukaemia_ ) , the body produces many abnormal white blood cells _(lymphocytes)_ and lymph nodes start to grow in various parts of the body. The abnormal white blood cells cannot carry out the normal disease fighting functions and may push aside healthy blood cells. This can result in infections, a decrease in number of red blood cells _(anaemia)_ , bruising, severe bleeding or even organ failure. Fludara is used in the treatment of B-cell chronic lymphocytic leukaemia (B-CLL) in patients with sufficient healthy blood cell production. First treatment for chronic lymphocytic leukaemia with Fludara oral should only be started in patients with advanced disease having disease-related symptoms or evidence of disease progression. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE FLUDARA ORAL D Lestu allt skjalið
1. NAME OF THE MEDICINAL PRODUCT Fludara oral 10 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 10mg fludarabine phosphate. Excipients: Lactose monohydrate 74.75 mg For the full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Film-coated tablets. Salmon-pink, capsule-shaped tablet marked with ‘LN’ in a regular hexagon on one side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of B-cell chronic lymphocytic leukaemia (CLL) in adult patients with sufficient bone marrow reserves. First line treatment with Fludara oral should only be initiated in adult patients with advanced disease, Rai stages III/IV (Binet stage C) or Rai stages I/II (Binet stage A/B) where the patient has disease related symptoms or evidence of progressive disease. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The recommended dose is 40 mg fludarabine phosphate/m² body surface given daily for 5 consecutive days every 28 days by oral route. This dose corresponds to 1.6 times the recommended intravenous dose of fludarabine phosphate (25 mg/m 2 body surface per day). The following table provides guidance for determining the number of tablets of Fludara oral to be administered: BODY SURFACE AREA (BSA) [M²] CALCULATED TOTAL DAILY DOSE BASED ON BSA (ROUNDED UP OR DOWN TO WHOLE NUMBER) [MG/DAY] NUMBER OF TABLETS PER DAY (TOTAL DAILY DOSE) 0.75 - 0.88 30 – 35 3 (30 mg) 0.89 - 1.13 36 – 45 4 (40 mg) 1.14 - 1.38 46 – 55 5 (50 mg) 1.39 - 1.63 56 – 65 6 (60 mg) 1.64 - 1.88 66 – 75 7 (70 mg) 1.89 - 2.13 76 – 85 8 (80 mg) 2.14 - 2.38 86 – 95 9 (90 mg) 2.39 - 2.50 96 – 100 10 (100 mg) The duration of treatment depends on the success of treatment and the tolerability of the drug. Fludara oral should be administered until best response is achieved (complete or partial remission, usually 6 cycles) and then the drug should be discontinued. Dose adjustments for the first treatment cycle (start of therapy with Fludara) are not recommended (except in patients with Lestu allt skjalið